JAK2 mutations (V617F and exon 12) are nearly universal in patients with post-PV MF, whereas JAK2 V617F and CALR exon 9 indels are detected in approximately 50% and 30% of patients with post-ET MF, respectively [9]. This evidence concerns the gene JAK2 and essential thrombocythemia.